CytomX reports Phase I data for CX-072 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) reported preliminary data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as monotherapy and in combination

Read the full 200 word article

User Sign In